Subsequent studies confirmed the presence of IDH mutations in 70–90% of low-grade glioma and secondary glioblastoma, in ~20% of acute myeloid leukemia, and in intrahepatic cholangiocarcinoma, chondrosarcoma, and melanoma (36, 38, 39). This evidence concerns the gene IDH1 and central nervous system cancer.